Skip to main content

Climb Bio, Inc 8-K, filed Oct 26, 2026

Climb Bio, Inc. (CLYM)

8-K 2026-10-26 For: 2026-10-24
View Original
Added on October 26, 2026

About this 8-K

Climb Bio, Inc filed this 8-K on October 26, 2026, reporting on events of October 24, 2026.

Climb Bio reported initial PrisMN Phase 2 data for budoprutug in primary membranous nephropathy, with a mean PLA2R antibody reduction of 70% at Week 12 in the 200 mg cohort. The 600 mg cohort showed mean peripheral CD20+ B-cell suppression of 98% at Week 4, versus 74% at 200 mg. The drug was generally well tolerated, and additional Phase 2 data are anticipated in 2027. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits